1. Home
  2. PHK vs DNTH Comparison

PHK vs DNTH Comparison

Compare PHK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHK
  • DNTH
  • Stock Information
  • Founded
  • PHK 2003
  • DNTH 2015
  • Country
  • PHK United States
  • DNTH United States
  • Employees
  • PHK N/A
  • DNTH N/A
  • Industry
  • PHK Finance/Investors Services
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHK Finance
  • DNTH Health Care
  • Exchange
  • PHK Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • PHK 777.7M
  • DNTH 711.2M
  • IPO Year
  • PHK N/A
  • DNTH N/A
  • Fundamental
  • Price
  • PHK $4.89
  • DNTH $21.66
  • Analyst Decision
  • PHK
  • DNTH Strong Buy
  • Analyst Count
  • PHK 0
  • DNTH 9
  • Target Price
  • PHK N/A
  • DNTH $46.43
  • AVG Volume (30 Days)
  • PHK 491.5K
  • DNTH 285.9K
  • Earning Date
  • PHK 01-01-0001
  • DNTH 11-07-2024
  • Dividend Yield
  • PHK 12.61%
  • DNTH N/A
  • EPS Growth
  • PHK N/A
  • DNTH N/A
  • EPS
  • PHK N/A
  • DNTH N/A
  • Revenue
  • PHK N/A
  • DNTH $5,366,000.00
  • Revenue This Year
  • PHK N/A
  • DNTH $100.14
  • Revenue Next Year
  • PHK N/A
  • DNTH N/A
  • P/E Ratio
  • PHK N/A
  • DNTH N/A
  • Revenue Growth
  • PHK N/A
  • DNTH 51.41
  • 52 Week Low
  • PHK $4.13
  • DNTH $14.82
  • 52 Week High
  • PHK $5.15
  • DNTH $33.77
  • Technical
  • Relative Strength Index (RSI)
  • PHK 44.65
  • DNTH 45.12
  • Support Level
  • PHK $4.83
  • DNTH $18.72
  • Resistance Level
  • PHK $4.93
  • DNTH $28.65
  • Average True Range (ATR)
  • PHK 0.04
  • DNTH 2.31
  • MACD
  • PHK 0.00
  • DNTH -0.33
  • Stochastic Oscillator
  • PHK 42.86
  • DNTH 32.14

About PHK Pimco High Income Fund

PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: